Merck Begins Phase II/III Study of Investigational BACE Inhibitor, MK-8931 - Merck & Co (NYSE:MRK)

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

From Earlier: Merck (NYSE: MRK), known as MSD outside the United States and Canada,announced it has started a Phase II/III clinical trial designed to evaluatethe safety and efficacy of MK-8931 versus placebo in patients withmild-to-moderate Alzheimer's disease. MK-8931 is Merck's novel investigationaloral β-amyloid precursor protein site-cleaving enzyme (BACE) inhibitor, and isthe first with this mechanism to advance to this stage of clinical research.The global, multi-center study, called EPOCH, is designed to initiallyevaluate the safety of MK-8931 in a cohort of 200 patients prior to advancinginto a larger Phase III study.

Crypto Whales Are Loading Up — Are You?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!